Truist Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.31M | Buy |
4,007
+383
| +11% | +$125K | ﹤0.01% | 1464 |
|
|
2025
Q1 | $979K | Sell |
3,624
-774
| -18% | -$209K | ﹤0.01% | 1524 |
|
|
2024
Q4 | $1.03M | Buy |
4,398
+2,539
| +137% | +$597K | ﹤0.01% | 1527 |
|
|
2024
Q3 | $511K | Buy |
1,859
+131
| +8% | +$36K | ﹤0.01% | 1837 |
|
|
2024
Q2 | $420K | Sell |
1,728
-623
| -26% | -$151K | ﹤0.01% | 2070 |
|
|
2024
Q1 | $351K | Sell |
2,351
-127
| -5% | -$19K | ﹤0.01% | 2200 |
|
|
2023
Q4 | $474K | Buy |
+2,478
| New | +$474K | ﹤0.01% | 2009 |
|
|
2023
Q2 | – | Sell |
-1,328
| Closed | -$266K | – | 2551 |
|
|
2023
Q1 | $266K | Sell |
1,328
-140
| -10% | -$28K | ﹤0.01% | 2275 |
|
|
2022
Q4 | $349K | Buy |
+1,468
| New | +$349K | ﹤0.01% | 2171 |
|
|
2022
Q3 | – | Sell |
-5,000
| Closed | -$729K | – | 2501 |
|
|
2022
Q2 | $729K | Sell |
5,000
-1,924
| -28% | -$281K | ﹤0.01% | 1692 |
|
|
2022
Q1 | $1.13M | Sell |
6,924
-671
| -9% | -$110K | ﹤0.01% | 1567 |
|
|
2021
Q4 | $1.29M | Buy |
7,595
+992
| +15% | +$168K | ﹤0.01% | 1497 |
|
|
2021
Q3 | $1.25M | Buy |
6,603
+40
| +0.6% | +$7.55K | ﹤0.01% | 1479 |
|
|
2021
Q2 | $1.11M | Buy |
6,563
+838
| +15% | +$142K | ﹤0.01% | 1569 |
|
|
2021
Q1 | $808K | Buy |
5,725
+3,972
| +227% | +$561K | ﹤0.01% | 1701 |
|
|
2020
Q4 | $228K | Buy |
1,753
+374
| +27% | +$48.6K | ﹤0.01% | 2296 |
|
|
2020
Q3 | $201K | Sell |
1,379
-390
| -22% | -$56.8K | ﹤0.01% | 2231 |
|
|
2020
Q2 | $262K | Sell |
1,769
-168
| -9% | -$24.9K | ﹤0.01% | 2024 |
|
|
2020
Q1 | $211K | Sell |
1,937
-201
| -9% | -$21.9K | ﹤0.01% | 2066 |
|
|
2019
Q4 | $245K | Buy |
+2,138
| New | +$245K | ﹤0.01% | 2234 |
|